CTI Molecular Imaging posts double-digit gains in FY03

Revenue growth across all of its product and service segments propelled CTI Molecular Imaging Inc. to higher revenue totals in FY03, ending September 30. Revenues totaled $362.2 million, compared with $258.4 million in FY02.

 CPS Innovations, CTI's business units which develops and manufactures the company's PET and PET-CT systems, contributed revenues of $172 million in FY03, compared with $151.3 million in FY02. Net income rose to $20.6 million in FY03, compared with a net loss of $3.4 million in FY02. CTI also noted that it is "comfortable" with revenue projections in the range of $435 million to $445 million in FY04.

Around the web

Richard Heller III, MD, RSNA board member and senior VP of policy at Radiology Partners, offers an overview of policies in Congress that are directly impacting imaging.
 

The two companies aim to improve patient access to high-quality MRI scans by combining their artificial intelligence capabilities.

Positron, a New York-based nuclear imaging company, will now provide Upbeat Cardiology Solutions with advanced PET/CT systems and services.